Antiandrogen therapy induces mitochondrial oxidative phosphorylation to promote castration resistance in prostate cancer - PubMed
4 hours ago
- #Castration-Resistant Prostate Cancer
- #Mitochondrial OXPHOS
- #Metabolic Remodeling
- Antiandrogen therapy increases mitochondrial oxidative phosphorylation (OXPHOS) in prostate cancer cells without altering glycolysis.
- This metabolic shift, fueled by glucose and glutamine, is driven by activation of the ROS/AMPK/SIRT1/PGC-1α pathway.
- Enhanced OXPHOS contributes to castration resistance, and targeting the PGC-1α/OXPHOS axis can restore drug sensitivity and suppress tumor growth.